Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Website: theseusrx.com




Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$0.02 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 33.2% (LTM)

Entry Point: Share price is 91.7% higher than minimum and 69.5% lower than maximum for the last 3 years

Key Financials (Download financials)

Ticker: THRX
Share price, USD:  (0.0%)4.065
year average price 4.07  


year start price 4.07 2025-02-08

max close price 4.07 2025-02-08

min close price 4.07 2025-02-08

current price 4.07 2026-02-07
Common stocks: 38 490 104

Dividend Yield:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue):
Fundamental value created in LTM:
Market Cap ($m): 156
Net Debt ($m): -142
EV (Enterprise Value): 14
Price to Book: 0.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2023-12-29Zacks Investment Research

Is Theseus Pharmaceuticals (THRX) Stock a Solid Choice Right Now?

2023-11-27Zacks Investment Research

Theseus (THRX) Up 57% in a Month on Strategic Restructuring Plan

2023-09-29Seeking Alpha

Theseus Pharmaceuticals: Picking Up The Pieces After A Lead Failure

2023-08-11Zacks Investment Research

Down -65.65% in 4 Weeks, Here's Why You Should You Buy the Dip in Theseus Pharmaceuticals, Inc. (THRX)

2023-07-18Zacks Investment Research

After Plunging -69.57% in 4 Weeks, Here's Why the Trend Might Reverse for Theseus Pharmaceuticals, Inc. (THRX)

2023-07-17Zacks Investment Research

Theseus (THRX) Falls 72% on Decision to Discontinue GIST Study

2023-07-14InvestorPlace

Why Is Theseus Pharmaceuticals (THRX) Stock Down 68% Today?

2023-07-13Market Watch

Theseus Pharmaceuticals stock plummets after cancer drug development stopped

2023-04-04Zacks Investment Research

Wall Street Analysts See a 128.83% Upside in Theseus Pharmaceuticals, Inc. (THRX): Can the Stock Really Move This High?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4 2019 q4
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31 2019-12-31
symbol THRX THRX THRX THRX THRX THRX THRX THRX
reportedCurrency USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2023-11-17 2023-08-10 2023-05-11 2022-11-03
acceptedDate 2023-11-17 16:01:52 2023-08-10 07:06:16 2023-05-11 07:12:20 2023-03-09 07:15:36 2022-11-03 07:05:34 2022-03-10 07:23:10 2020-12-31 00:00:00 2019-12-31 00:00:00
calendarYear 2023 2023 2023 2022
period Q3 Q2 Q1 FY Q3 FY FY FY
revenue 0 0 0 0 0 0 0 0
costOfRevenue 22 507 158 709 0 438 000 0 2000 2000 2000
grossProfit -22 507 -158 709 0 -438 000 0 -2000 -2000 -2000
grossProfitRatio 0 0 0 0
researchAndDevelopmentExpenses 12M 13M 12M 36M 11M 18M 6M 4M
generalAndAdministrativeExpenses 5M 5M 5M 18M 5M 9M 878 000 818 000
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 5M 5M 5M 18M 5M 9M 878 000 818 000
otherExpenses 0 0 2M 0 0 28 000 0 0
operatingExpenses 16M 18M 17M 54M 16M 27M 7M 5M
costAndExpenses 16M 18M 17M 54M 16M 27M 7M 5M
interestIncome 3M 3M 0 0 0 28 0 0
interestExpense 0 0 -2M 0 -1M 0 0 0
depreciationAndAmortization 22 000 21 000 20 000 50 000 18 000 2000 2000 2000
ebitda -16M -18M -17M -54M -16M -27M -7M -5M
ebitdaratio 0 0 0 0
operatingIncome -16M -18M -17M -54M -16M -27M -7M -5M
operatingIncomeRatio 0 0 0 0
totalOtherIncomeExpensesNet 3M 3M 2M 3M 1M 28 000 -5M -2M
incomeBeforeTax -14M -15M -15M -51M -15M -27M -12M -7M
incomeBeforeTaxRatio 0 0 0 0
incomeTaxExpense 0 0 -2M -4M -1M 0 0 0
netIncome -14M -15M -12M -47M -14M -27M -12M -7M
netIncomeRatio 0 0 0 0
eps -0.31 -0.34 -0.29 -1.22 -0.35 -0.76 -0.47 -0.28
epsdiluted -0.31 -0.34 -0.29 -0.35
weightedAverageShsOut 44M 44M 42M 38M 39M 36M 25M 25M
weightedAverageShsOutDil 44M 44M 42M 38M 39M 36M 25M 25M
link Link Link Link Link
finalLink Link Link Link Link
filingDate 2023-03-09 2022-03-10 2020-12-31 2019-12-31
fiscalYear 2022 2021 2020 2019
netInterestIncome 0 28 0 0
ebit -54M -27M -7M -5M
nonOperatingIncomeExcludingInterest 50 000 0 0 0
netIncomeFromContinuingOperations -47M -27M -12M -7M
netIncomeFromDiscontinuedOperations 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0
netIncomeDeductions 0 0 0 0
bottomLineNetIncome -47M -27M -12M -7M
epsDiluted -1.22 -0.76 -0.47 -0.28

Balance Sheet Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4 2019 q4
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31 2019-12-31
symbol THRX THRX THRX THRX THRX THRX THRX THRX
reportedCurrency USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2023-11-17 2023-08-10 2023-05-11 2022-11-03
acceptedDate 2023-11-17 16:01:52 2023-08-10 07:06:16 2023-05-11 07:12:20 2023-03-09 07:15:36 2022-11-03 07:05:34 2022-03-10 07:23:10 2020-12-31 00:00:00 2019-12-31 00:00:00
calendarYear 2023 2023 2023 2022
period Q3 Q2 Q1 FY Q3 FY FY FY
cashAndCashEquivalents 47M 47M 110M 95M 116M 245M 8M 1M
shortTermInvestments 158M 161M 127M 103M 97M 0 0 0
cashAndShortTermInvestments 205M 208M 237M 198M 212M 245M 8M 1M
netReceivables 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0
otherCurrentAssets 4M 6M 6M 4M 3M 3M 113 000 64 000
totalCurrentAssets 210M 214M 237M 198M 215M 248M 9M 1M
propertyPlantEquipmentNet 4M 4M 5M 5M 5M 11 000 1000 3000
goodwill 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0
longTermInvestments 20M 26M 7M 14M 9M 379 000 0 0
taxAssets 0 0 0 0 0 0 0 0
otherNonCurrentAssets 399 000 794 000 7M 6M 2M 3M 43 000 43 000
totalNonCurrentAssets 25M 31M 19M 24M 15M 3M 44 000 46 000
otherAssets 0 0 0 0 0 0 0 0
totalAssets 235M 245M 256M 222M 230M 251M 9M 1M
accountPayables 1M 2M 2M 5M 2M 1M 1M 285 000
shortTermDebt 759 000 754 000 748 000 743 000 779 000 0 0 0
taxPayables 0 0 0 0 0 0 0 0
deferredRevenue 5M 4M 0 0 0 0 0 0
otherCurrentLiabilities 349 000 5M 4M 5M 5M 3M 463 000 330 000
totalCurrentLiabilities 7M 8M 7M 11M 8M 4M 2M 615 000
longTermDebt 3M 3M 3M 3M 3M 0 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 205 000 292 000 379 000 466 000 1M 815 000 41M 10M
totalNonCurrentLiabilities 3M 3M 4M 4M 4M 815 000 41M 10M
otherLiabilities 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 0 4M 0 4M 0 0 0
totalLiabilities 10M 11M 10M 15M 12M 4M 43M 11M
preferredStock 0 0 0 0 0 251M 0 0
commonStock 4000 4000 4000 4000 4000 4000 0 0
retainedEarnings -155M -142M -127M -112M -98M -62M -34M -10M
accumulatedOtherComprehensiveIncomeLoss -345 000 -561 000 -159 000 -386 000 -550 000 -251M 0 813 000
othertotalStockholdersEquity 380M 376M 372M 318M
totalStockholdersEquity 225M 234M 245M 208M 219M 246M -34M -9M
totalEquity 225M 234M 245M 208M 219M 246M -34M -9M
totalLiabilitiesAndStockholdersEquity 235M 245M 256M 230M
minorityInterest 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 235M 245M 256M 222M 230M 251M 9M 1M
totalInvestments 179M 187M 134M 117M 105M 379 000 0 0
totalDebt 4M 4M 4M 4M 4M 0 0 0
netDebt -43M -44M -106M -91M -111M -245M -8M -1M
link Link Link Link Link
finalLink Link Link Link Link
filingDate 2023-03-09 2022-03-10 2020-12-31 2019-12-31
fiscalYear 2022 2021 2020 2019
accountsReceivables 0 0 0 0
otherReceivables 0 0 0 0
prepaids 0 0 0 0
totalPayables 5M 1M 1M 285 000
otherPayables 0 0 0 0
accruedExpenses 0 0 0 0
capitalLeaseObligationsCurrent 0 0 0 0
capitalLeaseObligationsNonCurrent 0 0 0 0
treasuryStock 0 0 0 0
additionalPaidInCapital 0 0 0 0
otherTotalStockholdersEquity 320M 308M 0 -6M

Cash Flow Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4 2019 q4
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31 2019-12-31
symbol THRX THRX THRX THRX THRX THRX THRX THRX
reportedCurrency USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2023-11-17 2023-08-10 2023-05-11 2022-11-03
acceptedDate 2023-11-17 16:01:52 2023-08-10 07:06:16 2023-05-11 07:12:20 2023-03-09 07:15:36 2022-11-03 07:05:34 2022-03-10 07:23:10 2020-12-31 00:00:00 2019-12-31 00:00:00
calendarYear 2023 2023 2023 2022
period Q3 Q2 Q1 FY Q3 FY FY FY
netIncome -14M -15M -15M -51M -15M -27M -12M -7M
depreciationAndAmortization 22 000 21 000 20 000 50 000 18 000 2000 2000 2000
deferredIncomeTax -2M -1M 0 0 0 -4M 0 0
stockBasedCompensation 4M 4M 3M 11M 4M 4M 1M 317 000
changeInWorkingCapital 356 000 2M -6M 7M 3M -4M 933 000 -179 000
accountsReceivables 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0
accountsPayables -1M 191 000 -3M 4M 314 000 -150 000 849 000 193 000
otherWorkingCapital 1M 2M 3M 3M 2M -4M 84 000 -372 000
otherNonCashItems 194 000 53 000 -598 000 -350 000 252 000 4M 5M 2M
netCashProvidedByOperatingActivities -11M -10M -19M -33M -7M -27M -5M -5M
investmentsInPropertyPlantAndEquipment -50 000 -11 000 11 000 -455 000 -63 000 12 000 0 0
acquisitionsNet 0 51 928 0 116 839 0 0 0 0
purchasesOfInvestments -10M -83M -57M -191M -62M 0 0 0
salesMaturitiesOfInvestments 20M 31M 41M 75M 0 0 0 0
otherInvestingActivites 0 -51 928 -11 000 50M
netCashUsedForInvestingActivites 10M -52M -16M -12M
debtRepayment 0 0 0 0
commonStockIssued 0 142 000 49M 0
commonStockRepurchased 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0
otherFinancingActivites 0 142 000 48 000 0
netCashUsedProvidedByFinancingActivities 0 142 000 49M 0
effectOfForexChangesOnCash 0 0 0 0 0 -12 000 0 0
netChangeInCash -949 000 -62M 15M -150M -20M 237M 7M -2M
cashAtEndOfPeriod 47M 48M 110M 95M 116M 245M 8M 1M
cashAtBeginningOfPeriod 48M 110M 95M 245M 135M 8M 1M 3M
operatingCashFlow -11M -10M -19M -33M -7M -27M -5M -5M
capitalExpenditure -50 000 -11 000 11 000 -455 000 -63 000 12 000 0 0
freeCashFlow -11M -10M -19M -33M -7M -27M -5M -5M
link Link Link Link Link
finalLink Link Link Link Link
filingDate 2023-03-09 2022-03-10 2020-12-31 2019-12-31
fiscalYear 2022 2021 2020 2019
otherInvestingActivities -116 839 0 0 0
netCashProvidedByInvestingActivities -117M 12 000 0 0
netDebtIssuance 0 0 0 0
longTermNetDebtIssuance 0 0 0 0
shortTermNetDebtIssuance 0 0 0 0
netStockIssuance 0 0 0 0
netCommonStockIssuance 0 0 0 0
commonStockIssuance 0 166M 12M 3M
netPreferredStockIssuance 0 0 0 0
netDividendsPaid 0 0 0 0
commonDividendsPaid 0 0 0 0
preferredDividendsPaid 0 0 0 0
otherFinancingActivities 182 000 264M 12M 3M
netCashProvidedByFinancingActivities 182 264M 12M 3M
incomeTaxesPaid 0 0 0 0
interestPaid 0 0 0 0

Earning call transcript

SEC forms

Show financial reports only

SEC form 10
2023-11-17 16:01 ET
Theseus Pharmaceuticals, Inc. reported for 2023 q3
SEC form 10
2023-11-17 00:00 ET
Theseus Pharmaceuticals, Inc. reported for 2023 q3
SEC form 8
2023-11-13 16:06 ET
Theseus Pharmaceuticals, Inc. published news for 2023 q3
SEC form 10
2023-08-10 07:06 ET
Theseus Pharmaceuticals, Inc. reported for 2023 q2
SEC form 6
2023-08-10 07:05 ET
Theseus Pharmaceuticals, Inc. reported for 2023 q2
SEC form 8
2023-08-10 00:00 ET
Theseus Pharmaceuticals, Inc. reported for 2023 q2
SEC form 10
2023-08-10 00:00 ET
Theseus Pharmaceuticals, Inc. reported for 2023 q2
SEC form 6
2023-07-13 16:08 ET
Theseus Pharmaceuticals, Inc. published news for 2023 q2
SEC form 8
2023-07-13 00:00 ET
Theseus Pharmaceuticals, Inc. published news for 2023 q2
SEC form 10
2023-05-11 07:12 ET
Theseus Pharmaceuticals, Inc. reported for 2023 q1
SEC form 6
2023-05-11 07:09 ET
Theseus Pharmaceuticals, Inc. reported for 2023 q1
SEC form 8
2023-05-11 00:00 ET
Theseus Pharmaceuticals, Inc. reported for 2023 q1
SEC form 10
2023-05-11 00:00 ET
Theseus Pharmaceuticals, Inc. reported for 2023 q1
SEC form 6
2023-04-26 09:00 ET
Theseus Pharmaceuticals, Inc. published news for 2023 q1
SEC form 6
2023-04-14 09:00 ET
Theseus Pharmaceuticals, Inc. published news for 2023 q1
SEC form 10
2023-03-09 07:15 ET
Theseus Pharmaceuticals, Inc. reported for 2022 q4
SEC form 6
2023-03-09 07:00 ET
Theseus Pharmaceuticals, Inc. reported for 2022 q4
SEC form 8
2023-03-09 00:00 ET
Theseus Pharmaceuticals, Inc. reported for 2022 q4
SEC form 10
2023-03-09 00:00 ET
Theseus Pharmaceuticals, Inc. reported for 2022 q4
SEC form 6
2023-01-05 07:02 ET
Theseus Pharmaceuticals, Inc. published news for 2022 q4
SEC form 8
2023-01-05 00:00 ET
Theseus Pharmaceuticals, Inc. published news for 2022 q4
SEC form 10
2022-11-03 07:05 ET
Theseus Pharmaceuticals, Inc. reported for 2022 q3
SEC form 6
2022-11-03 07:00 ET
Theseus Pharmaceuticals, Inc. reported for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Theseus Pharmaceuticals, Inc. reported for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Theseus Pharmaceuticals, Inc. reported for 2022 q3
SEC form 6
2022-10-19 07:16 ET
Theseus Pharmaceuticals, Inc. published news for 2022 q3
SEC form 6
2022-10-19 07:15 ET
Theseus Pharmaceuticals, Inc. published news for 2022 q3
SEC form 10
2022-08-11 07:18 ET
Theseus Pharmaceuticals, Inc. reported for 2022 q2
SEC form 6
2022-08-11 07:15 ET
Theseus Pharmaceuticals, Inc. reported for 2022 q2
SEC form 10
2022-08-11 00:00 ET
Theseus Pharmaceuticals, Inc. reported for 2022 q2
SEC form 8
2022-08-11 00:00 ET
Theseus Pharmaceuticals, Inc. reported for 2022 q2
SEC form 6
2022-06-13 16:39 ET
Theseus Pharmaceuticals, Inc. published news for 2022 q1
SEC form 6
2022-05-18 16:24 ET
Theseus Pharmaceuticals, Inc. published news for 2022 q1
SEC form 6
2022-05-18 16:22 ET
Theseus Pharmaceuticals, Inc. published news for 2022 q1
SEC form 10
2022-05-12 07:21 ET
Theseus Pharmaceuticals, Inc. reported for 2022 q1
SEC form 6
2022-05-12 07:15 ET
Theseus Pharmaceuticals, Inc. published news for 2022 q1
SEC form 10
2022-05-12 00:00 ET
Theseus Pharmaceuticals, Inc. reported for 2022 q1
SEC form 8
2022-05-12 00:00 ET
Theseus Pharmaceuticals, Inc. reported for 2022 q1
SEC form 6
2022-04-25 16:30 ET
Theseus Pharmaceuticals, Inc. published news for 2022 q1
SEC form 10
2022-03-10 07:23 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q4
SEC form 6
2022-03-10 07:15 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q4
SEC form 8
2022-03-10 00:00 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q4
SEC form 10
2022-03-10 00:00 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q4
SEC form 6
2022-01-10 07:16 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q4
SEC form 10
2021-11-15 07:36 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q3
SEC form 6
2021-11-15 07:30 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q3
SEC form 10
2021-11-15 00:00 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q3
SEC form 8
2021-11-15 00:00 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q3
SEC form 6
2021-10-27 16:14 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q3
SEC form 6
2021-10-06 19:01 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q3
SEC form 6
2021-10-06 19:01 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q3
SEC form 6
2021-10-06 19:01 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q3
SEC form 6
2021-10-06 19:00 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q3
SEC form 6
2021-10-06 19:00 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q3
SEC form 6
2021-10-06 19:00 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q3
SEC form 6
2021-10-06 19:00 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q3
SEC form 6
2021-10-06 19:00 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q3
SEC form 6
2021-10-06 19:00 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q3
SEC form 6
2021-10-06 19:00 ET
Theseus Pharmaceuticals, Inc. published news for 2021 q3